Showing 1951-1960 of 2494 results for "".
- SpyGlass Pharma Appoints Industry Veteran Patrick Mooney as Chief Executive Officerhttps://modernod.com/news/spyglass-pharma-appoints-industry-veteran-patrick-mooney-as-chief-executive-officer/2479389/SpyGlass Pharma has appointed industry veteran Patrick Mooney as Chief Executive Officer. This appointment coincides with broad company expansion and relocation to new headquarters in Aliso Viejo, California. “We are excited to bring Patrick to
- Euclid Systems Appoints Vance Thompson, MD, as Chief Medical Officerhttps://modernod.com/news/euclid-systems-appoints-vance-thompson-md-as-chief-medical-officer/2479383/Euclid Systems announced that it has appointed Vance Thompson, MD, an internationally recognized authority in laser vision correction and advanced cataract surgery, to the position of Chief Medical Officer. As an international researcher, Dr. Thompson has played a key role in the development of a
- Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officerhttps://modernod.com/news/outlook-therapeutics-appoints-c-russell-trenary-iii-as-president-and-chief-executive-officer/2479350/Outlook Therapeutics announced the appointment of C. Russell Trenary III as President, Chief Executive Officer and a member of the Board of Directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics’ President, CEO and CFO since June 2018, will continue serving as CFO and as a member o
- Belkin Laser Appoints Andrew Webb as Chief Commercial Officerhttps://modernod.com/news/belkin-laser-appoints-andrew-webb-as-chief-commercial-officer/2479316/Israel-based medical device company Belkin Laser has announced the appointment of Andrew Webb as Chief Commercial Officer. Under Mr. Webb’s guidance, the company’s commercial and go-to-market strategy will be rolled out in anticipation of a controlled launch in
- Arnaud Lacoste Is Named Chief Scientific Officer of Aurion Biotechhttps://modernod.com/news/arnaud-lacoste-is-named-chief-scientific-officer-of-aurion-biotech/2479293/Arnaud Lacoste, MBA, PhD, has been named chief scientific officer of Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies. Arnaud will lead R&D teams based in Boston and Seattle. “Arnaud is a brilliant scientist, a strategic e
- Oxular Appoints Dr. Friedrich Asmus as Chief Medical Officerhttps://modernod.com/news/oxular-appoints-dr-friedrich-asmus-as-chief-medical-officer/2479267/Oxular Limited announced it has appointed Friedrich (Fritz) Asmus, MD, as Chief Medical Officer. Dr. Asmus will lead all medical, clinical, and regulatory functions to further the company’s lead asset, OXU‑001, for the treatment of diabetic macular edema (DME), and to accelerate the development o
- Oxurion Appoints Tom Graney, CFA, as Chief Executive Officerhttps://modernod.com/news/oxurion-appoints-tom-graney-cfa-as-chief-executive-officer/2479215/Oxurion NV announced in a planned succession, the promotion of Tom Graney, CFA, from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Patrik De Haes, MD, who after 14 years as CEO has decided to move away from day-to-day management
- Gyroscope Therapeutics Postpones Initial Public Offeringhttps://modernod.com/news/gyroscope-therapeutics-postpones-initial-public-offering/2479176/Gyroscope Therapeutics announced it has postponed plans for its initial public offering. “In light of market conditions, we have decided to postpone our planned initial public offering,” Khurem Farooq, Chief Executive Officer, said in a company news release. “Based on the
- Foundation Fighting Blindness Appoints Claire M. Gelfman, PhD, as Chief Scientific Officerhttps://modernod.com/news/foundation-fighting-blindness-appoints-claire-m-gelfman-phd-as-chief-scientific-officer/2479118/Foundation Fighting Blindness announced that it has appointed Claire M. Gelfman, PhD, as chief scientific officer. In her new role, Dr. Gelfman will be responsible for leading the overarching scientific strategy for the organization with a focus on research initiati
- US Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucomahttps://modernod.com/news/us-patent-office-issues-notice-of-allowance-for-nicoxs-latanoprostene-bunod-in-normal-tension-glaucoma/2479119/Nicoy announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent covering the use of latanoprostene bunod for the treatment of normal tension glaucoma. Latanoprostene bunod ophthalmic solution, 0.024%, is commercialized as Vyzulta for